ASCO 2021 | CADMUS trial: multiparametric ultrasound in prostate cancer diagnosis

Alistair Grey, FRCS (Urol), University College London, London, UK, discusses the results of the CADMUS trial (ISRCTN38541912): a prospective paired cohort trial comparing multiparametric ultrasound (mpUSS) with multiparametric MRI (mpMRI) targeted biopsies in the detection of clinically significant prostate cancer. 306 patients underwent both mpUSS and mpMRI independently, and those with a positive result in either test were advised to undergo targeted biopsies. The performance of mpUSS was comparable to that of mpMRI, with an agreement in the detection of clinically significant prostate cancer of over 91%. mpUSS detected around 4% less clinically significant prostate cancer. Using both scans together increased overall and clinically significant cancer detection. The findings from the CADMUS trial may lead to the deployment of mpUSS as a cheaper, more accessible alternative to mpMRI for the detection of prostate cancer and may lead to the use of both technologies, in combination, to improve diagnosis. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.